论文部分内容阅读
卵巢恶性肿瘤是女性常见的恶性肿瘤,发病率在女性生殖道肿瘤中位于第3位,但死亡率却位居女性生殖道肿瘤之首。由于早期症状隐匿,接近2/3的患者诊断时已为Ⅲ期或Ⅳ期,5年生存率明显低于Ⅰ期或Ⅱ期。由于早期卵巢癌的预后要明显好于晚期卵巢癌,卵巢癌的早期诊断已成为提高患者生存率的一项重要的因素。血清癌抗原125(CA125)ELISA检查已常规用于卵巢癌的诊断和病情监测,本文拟就CA125目前在卵巢癌临床工作中的应用及近年相关新的研究进展作一综述。
Ovarian malignancies are common malignant tumors in women, the incidence of female reproductive tract tumors located in the first three, but the mortality rate is ranked first in female genital tract tumors. Due to the early symptoms of occult, nearly two-thirds of patients diagnosed at stage III or IV, 5-year survival rate was significantly lower than in stage I or II. Since the prognosis of early ovarian cancer is significantly better than advanced ovarian cancer, early diagnosis of ovarian cancer has become an important factor in improving patient survival. Serum CA125 (CA125) ELISA has been routinely used in the diagnosis and condition monitoring of ovarian cancer. This paper reviews the current clinical application of CA125 in ovarian cancer and the recent progress in its research.